Abstract
Soon after commencement of the SARS-CoV-2 disease outbreak of 2019 (COVID-19), it became evident that the receptor-binding domain of the viral spike protein is the target of neutralizing antibodies that comprise a critical element of protective immunity to the virus. This study addresses the relative lack of information regarding actual antibody concentrations in convalescent plasma samples from COVID-19 patients and extends these analyses to post-vaccination samples to estimate protective IgG antibody (Ab) levels. Both sample populations were similar and a protective Ab level of 7.5 µg/ml was determined, based on 95% of the normal distribution of the post-vaccination population. The results of this study have implications for future vaccine development, projection of protective efficacy duration, and understanding of the immune response to SARS-CoV-2 infection.
One-Sentence Summary Using two quantitative immunoassays, we have found similar IgG antibody responses to the SARS-CoV-2 spike protein in populations of COVID-19 survivors and vaccine recipients that indicate a protective antibody concentration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Texas A&M University System, BADAS Study (Bacillus Calmette-Guérin Vaccination as defense against SARS-CoV-2. A Randomized Placebo-Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses) (MEK, JDC, KK) Biostatistics/ Epidemiology/Research Design (BERD) component of the Center for Clinical and Translational Sciences (CCTS), mainly funded by a grant (UL1 TR003167) from the National Center for Advancing Translational Sciences (NCATS), awarded to The University of Texas Health Science Center at Houston (UTHealth) (MHR, MH, AT)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Texas Health Science Center Committee for the Protection of Human Subjects approved by expedited review and approval on June 24, 2020. IRB Approval No. HSC-MS-20-0606
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Small quantities of plasma samples are available to researchers for purposes of reproducing or extending the analysis, subject to materials transfer agreements. Raw data not included in the supplementary materials are available by individual arrangement.
